Tofisopam
SIGMA/T8200 - ≥98% (HPLC), solid
Synonym: 7,8-
CAS Number: 22345-47-7
Empirical Formula (Hill Notation): C22H26N2O4
Molecular Weight: 382.45
EC Number: 244-922-3
MDL Number: MFCD00823171
Linear Formula: C22H26N2O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| drug control | regulated under CDSA - not available from Sigma-Aldrich Canada |
| form | solid |
| InChI | 1S/C22H26N2O4/c1-7-15-13( |
| InChI key | RUJBDQSFYCKFAA-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | CCC1C(C)=NN=C(c2ccc(OC)c( |
| solubility | DMSO: ~14 mg/mL |
| H2O: insoluble |
| Application: | Tofisopam has been used for studying its biochemical mechanisms of actions using drug repositioning strategies. |
| Biochem/physiol Actions: | Ligand for the GABAA receptor benzodiazepine modulatory site. |
| Biochem/physiol Actions: | Studies have reported that tofisopam functions by blocking PDE4 (phosphodiesterase 4). Furthermore, the S-enantiomer of tofisopam is considered ten times more active than R-enantiomer. |
| Packaging: | 10, 50 mg in glass bottle |
| Preparation Note: | Tofisopam is soluble in DMSO at approximately 14 mg/ml. However, it is insoluble in water. |
| Symbol | ![]() GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | H302 - H400 |
| Precautionary statements | P273 - P301 + P312 + P330 |
| Hazard Codes | Xn,N |
| Risk Statements | 22-50 |
| Safety Statements | 60-61 |
| RIDADR | UN 3077 9 / PGIII |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| UNSPSC | 12352200 |



